# Advisor Review - Advisor 1/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-27T11:10:21.995504
**Response ID:** resp_0c6bd8d59d7b882000697871cf30888195acecd69a21a64a6e
**Tokens:** 10132 in / 11187 out
**Response SHA256:** 6df42519d6f78441

---

## 1) Data–Design Alignment (critical)
- **Treatment timing vs. data coverage:** All treated cohorts’ *first full treated years* (2010, 2014, 2018, 2020, 2021, 2022) are **≤ max data year (2023)**. No cohort is defined as treated in a year beyond the panel.
- **Post-treatment observations exist:** Each treated cohort has post-treatment years observed in the ACS panel (e.g., CT: 2022–2023; DC/MA: 2021–2023; WA: 2021–2023 given ACS-2020 absence).
- **Treatment definition consistency:** The “first full treated year” rule in Table 1 matches the treatment definition described in the Data Appendix and used throughout the empirical design. Dropping NJ-2009 and OR-2023 for partial-year exposure is consistent with the stated rule.

## 2) Regression Sanity (critical)
Checked **Table 3** and **Table 4**:
- Coefficients are in plausible units (percentage points) and magnitudes (|ATT| < 0.3 pp throughout).
- Standard errors are plausible and not indicative of collinearity/pathology (no huge SEs; no SEs orders of magnitude larger than coefficients).
- No impossible values (no negative SEs; no NA/NaN/Inf shown; no invalid statistics shown).

## 3) Completeness (critical)
- Regression tables report **standard errors and sample sizes (N)** (Tables 3–4).
- Figures and tables referenced in the text (Figures 1–4, Tables 1–4) appear to exist in the draft excerpt provided.
- No placeholders (TBD/TODO/XXX/NA) appear in tables/estimates shown.

## 4) Internal Consistency (critical)
- Key numbers cited in text match the tables (e.g., ATT −0.187 with SE 0.140; CI consistent with that SE; baseline 7.41% used for percent-of-baseline calculations).
- Sample size arithmetic is consistent (918 potential state-years; minus 2 dropped transition observations = 916; minus CA’s 18 always-treated years for CS = 898).

ADVISOR VERDICT: PASS